Case series discussion of cardiac and vascular events following carfilzomib treatment: possible mechanism, screening, and monitoring.

ABSTRACT:

Background

Carfilzomib is a selective proteasome inhibitor approved in the United States in 2012 for the treatment of relapsed and refractory multiple myeloma. Although cardiopulmonary and vascular events have been reported infrequently, they can be potentially serious complications, and their incidence and pathophysiology following carfilzomib treatment remain poorly characterized in a real-world patient population.

Methods

We retrospectively reviewed the records of 67 patients with relapsed and/or refractory multiple myeloma treated at our institution.

Results

We describe 12 patients who experienced cardiac or vascular-related adverse events subsequent to carfilzomib-based treatment (median age, 59 years [range, 49-77]). Nine patients had prior autologous stem cell

SUBMITTER: Chari A 

PROVIDER: S-EPMC4289164 | biostudies-literature | 2014 Dec

REPOSITORIES: biostudies-literature